Drug intelligence / Profile preview

RVX-003

Development stage: Preclinical
Lead developer: ReNewVax
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

RVX-003 is a preclinical-stage recombinant protein vaccine being developed by ReNewVax to prevent infections caused by *Streptococcus pyogenes* (Group A Streptococcus, or GAS). The vaccine is designed to target conserved antigens that cover more than 60% of disease-causing emm types. By inducing immunity against these conserved components, RVX-003 aims to provide broad protection against a range of GAS-related conditions, including strep throat, necrotizing fasciitis, and toxic shock syndrome, as well as post-infectious complications such as acute rheumatic fever and rheumatic heart disease.

Targets

RVX-003 (Conserved Streptococcus pyogenes protein antigens)

Beyond the preview

Go deeper on RVX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVX-003.

Explore the full profile